DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-781

MAY 14 1998

Schering-Plough Research Institute
Attention: Joseph Lamendola, Ph.D.
Vice President, U.S. Regulatory Affairs
Galloping Hill Road
Kenilworth, NJ 07033

Dear Dr. Lamendola:

Please refer to your new drug application dated September 30, 1987, received October 8, 1987, and your resubmission dated March 17, 1989, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Prometrium (progesterone USP) Capsules, 100 mg.

We acknowledge receipt of your submissions dated July 25, 1997; and March 19, April 29, and May 1, 6, and 13, 1998, in response to our approvable letter dated March 28, 1997.

This new drug application provides for the treatment of secondary amenorrhea in premenopausal women.

We have completed the review of this application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the draft labeling provided in the submission dated March 19 (cartons and labels), and May 6 (Physician Package Insert, and Patient Package Insert), 1998. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft labeling submitted on March 19 and May 6, 1998, respectively. Marketing the product with FPL that is not identical to this draft labeling may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FINAL PRINTED LABELING" for approved NDA 19-781. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you of your Phase 4 commitment specified in your submission dated November 12, 1996, as clarified in accordance with the telephone conversation between Ms. Paula Rinaldi of your office and Ms. Diane Moore of this Division on June 11, 1997, and your submission dated May 13, 1998. This commitment, along with any completion dates agreed upon, is listed below.

After the Phase 4 study is completed, revised labeling incorporating these data should be submitted.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. Should an IND not be required to meet your Phase 4 commitments, please submit protocol, data, and final reports to this NDA as correspondences. In addition, we request under 21 CFR 314.81(b)(2)(vii) that you include in your annual report to this application, a status summary of each commitment. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

In addition, please submit three copies of the introductory promotional material that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional material and the package insert directly to:

Food and Drug Administration
Division of Drug Marketing, Advertising and Communications,
HFD-40
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Diane Moore, Project Manager, at (301) 827-4260.

Sincerely,

Lisa D. Rarick, M.D.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research